D048289Chemicals & DrugsD03.383.129.308.432450.998911Imidazolidinesprns:emailEncryptedemail addressprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson15146479El-Kabbani O, Darmanin C, Schneider TR, Hazemann I, Ruiz F, Oka M, Joachimiak A, Schulze-Briese C, Tomizaki T, Mitschler A, Podjarny AProteinsUltrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors. Proteins. 2004 Jun 01; 55(4):805-13.Proteins2004-06-01T00:00:002004Ultrahigh resolution drug design. II. Atomic resolution structures of human aldose reductase holoenzyme complexed with Fidarestat and Minalrestat: implications for the binding of cyclic imide inhibitors.16153201Davis NB, Ryan CW, Stadler WM, Vogelzang NJBJU internationalA phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy. BJU Int. 2005 Oct; 96(6):787-90.BJU Int2005-10-01T00:00:002005A phase II study of nilutamide in men with prostate cancer after the failure of flutamide or bicalutamide therapy.6401351Judzewitsch RG, Jaspan JB, Polonsky KS, Weinberg CR, Halter JB, Halar E, Pfeifer MA, Vukadinovic C, Bernstein L, Schneider M, Liang KY, Gabbay KH, Rubenstein AH, Porte DThe New England journal of medicineAldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med. 1983 Jan 20; 308(3):119-25.N Engl J Med1983-01-20T00:00:001983Aldose reductase inhibition improves nerve conduction velocity in diabetic patients.3083212Jaspan JB, Towle VL, Maselli R, Herold KMetabolism: clinical and experimentalClinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism. 1986 Apr; 35(4 Suppl 1):83-92.Metabolism1986-04-01T00:00:001986Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes.11744479Desai A, Stadler WM, Vogelzang NJUrologyNilutamide: possible utility as a second-line hormonal agent. Urology. 2001 Dec; 58(6):1016-20.Urology2001-12-01T00:00:002001Nilutamide: possible utility as a second-line hormonal agent.Argonne National Laboratory0.1224780.01437674research area of0.277610.05756965subject area forMedicineNeurologyUniversity of ChicagoVernon LeoTowlewW59BLYZHMzMknJtY0fp/Cv/+94=Vernon Leo Towle41.78927490000000-87.601250000000001184Towle, Vernon LeoProfessorWalter M.StadlerWalter M. Stadler41.78927490000000-87.601250000000001904Stadler, Walter M.ProfessorKenneth S.PolonskyKenneth S. Polonsky41.78927490000000-87.601250000000002326Polonsky, Kenneth S.ProfessorAndrzejJoachimiakAndrzej Joachimiak41.78927490000000-87.60125000000000603Joachimiak, Andrzejtrue1true1ProfessorProfessortrue1ProfessorProfessortrue1ProfessorProfessorMedicine-Endocrinology